董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James A. Rechtin Chief Executive Officer and Non-Independent Director and President 55 1875.71万美元 4.43 2026-04-16
Karen W. Katz Independent Director 69 38.56万美元 0.06 2026-04-16
Wayne A. I. Frederick Independent Director 54 38.55万美元 0.04 2026-04-16
Raquel C. Bono Director 69 35.24万美元 0.04 2026-04-16
Marcy S. Klevorn Independent Director 66 38.24万美元 0.04 2026-04-16
Gordon Smith Independent Director 67 32.51万美元 0.08 2026-04-16
Frank A. D Amelio Independent Director 68 35.29万美元 2.06 2026-04-16
Kurt J. Hilzinger Chairman of the Board and Director 65 61.01万美元 1.94 2026-04-16
David T. Feinberg Independent Director 64 34.13万美元 0.04 2026-04-16
Jorge S. Mesquita Independent Director 64 36.61万美元 0.34 2026-04-16

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James A. Rechtin Chief Executive Officer and Non-Independent Director and President 55 1875.71万美元 4.43 2026-04-16
Celeste M. Mellet Chief Financial Officer 49 1892.27万美元 0.87 2026-04-16
Joseph C. Ventura Chief Legal Officer 49 310.22万美元 未持股 2026-04-16
Michelle A. O'Hara Chief Human Resources Officer 50 894.26万美元 0.08 2026-04-16
George Renaudin II President, Insurance 57 615.21万美元 未持股 2026-04-16
John Paul W. Felter Chief Accounting Officer and Controller and Senior Vice President 42 未披露 未持股 2026-04-16
Sanjay K. Shetty President, CenterWell 52 715.57万美元 0.91 2026-04-16
David E. Dintenfass President, Enterprise Growth 55 1806.16万美元 未持股 2026-04-16
Japan A. Mehta Chief Information Officer 45 956.46万美元 0.24 2026-04-16
Aaron C. Martin President, Medicare Advantage 56 未披露 未持股 2026-04-16

董事简历

中英对照 |  中文 |  英文
James A. Rechtin

James A. Rechtin, 2011年加入Humana, 2013年担任首席执行官。在过去的十年中,他领导公司从一家健康保险公司转型为今天的更广泛的医疗保健公司,将健康保险与医疗保健服务相结合。Rechtin从Envision Healthcare加入Humana,担任总裁兼首席执行官。他拥有超过22年的医疗保健经验,专注于在各种医疗集团环境中提供基于价值的护理,包括对医疗保险优势的深刻理解。加入Envision之前,Rechtin担任OptumCare (UnitedHealth Group的一部分)的总裁。在加入OptumCare之前,Rechtin于2014年加入DaVita Medical Group,担任战略高级副总裁和DaVita Medical Group加利福尼亚市场总裁。此外,他是Bain & Company的14年资深员工,突出了他在医疗保健合并和整体医疗保健行业的丰富经验。雷克廷是肯塔基人,他的职业生涯始于印第安纳波利斯一家非营利性健康和人类服务诊所的运营,并在刚果的美国和平队服役。他获得了哈佛商学院工商管理硕士学位和德堡大学文学学士学位。他担任DePauw board of Visitors的董事会成员。


James A. Rechtin joined Humana in January 2024, having served as President and Chief Operating Officer until July 2024. Under his leadership, Humana operates as a leading integrated care delivery model centered on improving health outcomes, driving lor costs, enhancing quality, and providing a simple and personalized member and patient experience.Prior to joining Humana, Mr. Rechtin served as President and CEO at Envision Healthcare. He has more than 22 years of health care experience with a foc on the delivery of value based care in vario medical group settings, including a deep understanding of Medicare Advantage. Prior to joining Envision, Mr. Rechtin served as President of OptumCare, part of UnitedHealth Group. Before that, Mr. Rechtin was with DaVita Medical Group and played the dual roles of Senior Vice President of Corporate Strategy and President of DaVita Medical Group's California market.
James A. Rechtin, 2011年加入Humana, 2013年担任首席执行官。在过去的十年中,他领导公司从一家健康保险公司转型为今天的更广泛的医疗保健公司,将健康保险与医疗保健服务相结合。Rechtin从Envision Healthcare加入Humana,担任总裁兼首席执行官。他拥有超过22年的医疗保健经验,专注于在各种医疗集团环境中提供基于价值的护理,包括对医疗保险优势的深刻理解。加入Envision之前,Rechtin担任OptumCare (UnitedHealth Group的一部分)的总裁。在加入OptumCare之前,Rechtin于2014年加入DaVita Medical Group,担任战略高级副总裁和DaVita Medical Group加利福尼亚市场总裁。此外,他是Bain & Company的14年资深员工,突出了他在医疗保健合并和整体医疗保健行业的丰富经验。雷克廷是肯塔基人,他的职业生涯始于印第安纳波利斯一家非营利性健康和人类服务诊所的运营,并在刚果的美国和平队服役。他获得了哈佛商学院工商管理硕士学位和德堡大学文学学士学位。他担任DePauw board of Visitors的董事会成员。
James A. Rechtin joined Humana in January 2024, having served as President and Chief Operating Officer until July 2024. Under his leadership, Humana operates as a leading integrated care delivery model centered on improving health outcomes, driving lor costs, enhancing quality, and providing a simple and personalized member and patient experience.Prior to joining Humana, Mr. Rechtin served as President and CEO at Envision Healthcare. He has more than 22 years of health care experience with a foc on the delivery of value based care in vario medical group settings, including a deep understanding of Medicare Advantage. Prior to joining Envision, Mr. Rechtin served as President of OptumCare, part of UnitedHealth Group. Before that, Mr. Rechtin was with DaVita Medical Group and played the dual roles of Senior Vice President of Corporate Strategy and President of DaVita Medical Group's California market.
Karen W. Katz

Karen W. Katz,最初于2019年9月当选为董事会成员。她最近担任Intermix, LLC的临时首席执行官(2022年6月至2022年12月)。在加入Intermix之前,她曾担任Neiman Marcus Group LTD LLC的总裁兼首席执行官(2010年至2018年2月)。内曼·马库斯集团是一家国际多品牌全渠道零售商,旗下品牌包括Neiman Marcus、Bergdorf Goodman和MyTheresa.自1985年加入Neiman Marcus以来,她曾担任公司商户、商店和电子商务组织的主要执行和领导职务,担任商店执行副总裁、Neiman Marcus Group主席办公室成员、Neiman Marcus Online总裁、Neiman Marcus stores总裁兼首席执行官。


Karen W. Katz was initially elected to the Board in September 2019. She was most recently interim CEO of Intermix, LLC from June 2022 to December 2022. Prior to Intermix, Ms. Katz served as the President and CEO of Neiman Marc Group LTD LLC from 2010 to February 2018. Under Ms. Katz's leadership, the company executed strategies foced on prioritizing the ctomer experience and technology integration. Neiman Marc Group is an international multibrand omni channel retailer whose portfolio of brands includes Neiman Marc, Bergdorf Goodman and MyTheresa. Having joined Neiman Marc in 1985, Ms. Katz served in key executive and leadership roles in the company's merchant, stores and eCommerce organizations as Executive Vice President—Stores, a member of the Office of the Chairman of Neiman Marc Group, and President, Neiman Marc Online, and President and CEO, Neiman Marc Stores.
Karen W. Katz,最初于2019年9月当选为董事会成员。她最近担任Intermix, LLC的临时首席执行官(2022年6月至2022年12月)。在加入Intermix之前,她曾担任Neiman Marcus Group LTD LLC的总裁兼首席执行官(2010年至2018年2月)。内曼·马库斯集团是一家国际多品牌全渠道零售商,旗下品牌包括Neiman Marcus、Bergdorf Goodman和MyTheresa.自1985年加入Neiman Marcus以来,她曾担任公司商户、商店和电子商务组织的主要执行和领导职务,担任商店执行副总裁、Neiman Marcus Group主席办公室成员、Neiman Marcus Online总裁、Neiman Marcus stores总裁兼首席执行官。
Karen W. Katz was initially elected to the Board in September 2019. She was most recently interim CEO of Intermix, LLC from June 2022 to December 2022. Prior to Intermix, Ms. Katz served as the President and CEO of Neiman Marc Group LTD LLC from 2010 to February 2018. Under Ms. Katz's leadership, the company executed strategies foced on prioritizing the ctomer experience and technology integration. Neiman Marc Group is an international multibrand omni channel retailer whose portfolio of brands includes Neiman Marc, Bergdorf Goodman and MyTheresa. Having joined Neiman Marc in 1985, Ms. Katz served in key executive and leadership roles in the company's merchant, stores and eCommerce organizations as Executive Vice President—Stores, a member of the Office of the Chairman of Neiman Marc Group, and President, Neiman Marc Online, and President and CEO, Neiman Marc Stores.
Wayne A. I. Frederick

Wayne A. I. Frederick,自2020年10月起担任董事会成员。自2024年11月2日起,他担任美国癌症协会及其倡导附属机构美国癌症协会癌症行动网络(ACS CAN)的临时首席执行官。他是Howard University College of Medicine杰出的Charles R. Drew外科教授,也是Howard University的名誉校长,此前曾担任Howard University的校长(2014年7月至2023年9月)。在2014年被任命为霍华德大学校长之前,他曾担任霍华德大学的教务长和首席学术官。Frederick博士是一名执业癌症外科医生,杰出的研究人员和学者,以及许多同行评审文章,书籍章节,摘要和社论的作者。作为医疗保健差异和医学教育领域公认的专家,他的医学研究重点是减少癌症治疗结果中的种族,民族和性别差异,特别强调胃肠道癌症。在他的职业生涯中,Frederick博士获得了许多认可,包括德克萨斯大学MD安德森癌症中心的杰出校友奖。2021年,他被纽约卡内基基金会(Carnegie Corporation of New York)表彰为加强美国做出贡献的34名入籍美国公民之一。他目前担任Humana, Inc., Tempus AI, Inc.和Workday, Inc.的董事会成员,并在担任临时首席执行官之前担任美国癌症协会董事会成员。他是几个专业协会的活跃成员,包括美国外科协会和美国外科医生学院。最近,他被任命为Mutual of America的高级独立董事,并担任波士顿咨询集团(Boston Consulting Group)的顾问。他获得了霍华德大学的理学学士、医学博士和工商管理硕士学位。


Wayne A. I. Frederick was initially elected to the Board in February 2020. He is the Interim President of Howard University, having been appointed to serve since September 1, 2025, and President Emerit having previoly served as the 17th President from July 2014 September 2023, and is the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine. He is also a practicing cancer surgeon at Howard University Hospital. Prior to that Dr. Frederick served as Howard University's Interim President (elected October 2013) after serving as Provost and Chief Academic Officer for more than a year.Following his post doctoral research and surgical oncology fellowships at the University of Texas MD Anderson Cancer Center, Dr. Frederick began his academic career as Associate Director of the Cancer Center at the University of Connecticut. Upon his return to Howard University, his academic positions included Associate Dean in the College of Medicine, Division Chief in the Department of Surgery, Director of the Cancer Center and Deputy Provost for Health Sciences. He also earned a Master of Biness Administration degree from Howard University's School of Biness in 2011.Dr. Frederick is a fellow of the American College of Surgeons (ACS) and belongs to numero surgical and medical organizations, including, the ACS' Academy of Master Surgeon Educators, the American Surgical Association and the National Academy of Medicine. In addition to his public board service, Dr. Frederick also serves on the Board of Directors of Mutual of America Life Insurance Co.
Wayne A. I. Frederick,自2020年10月起担任董事会成员。自2024年11月2日起,他担任美国癌症协会及其倡导附属机构美国癌症协会癌症行动网络(ACS CAN)的临时首席执行官。他是Howard University College of Medicine杰出的Charles R. Drew外科教授,也是Howard University的名誉校长,此前曾担任Howard University的校长(2014年7月至2023年9月)。在2014年被任命为霍华德大学校长之前,他曾担任霍华德大学的教务长和首席学术官。Frederick博士是一名执业癌症外科医生,杰出的研究人员和学者,以及许多同行评审文章,书籍章节,摘要和社论的作者。作为医疗保健差异和医学教育领域公认的专家,他的医学研究重点是减少癌症治疗结果中的种族,民族和性别差异,特别强调胃肠道癌症。在他的职业生涯中,Frederick博士获得了许多认可,包括德克萨斯大学MD安德森癌症中心的杰出校友奖。2021年,他被纽约卡内基基金会(Carnegie Corporation of New York)表彰为加强美国做出贡献的34名入籍美国公民之一。他目前担任Humana, Inc., Tempus AI, Inc.和Workday, Inc.的董事会成员,并在担任临时首席执行官之前担任美国癌症协会董事会成员。他是几个专业协会的活跃成员,包括美国外科协会和美国外科医生学院。最近,他被任命为Mutual of America的高级独立董事,并担任波士顿咨询集团(Boston Consulting Group)的顾问。他获得了霍华德大学的理学学士、医学博士和工商管理硕士学位。
Wayne A. I. Frederick was initially elected to the Board in February 2020. He is the Interim President of Howard University, having been appointed to serve since September 1, 2025, and President Emerit having previoly served as the 17th President from July 2014 September 2023, and is the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine. He is also a practicing cancer surgeon at Howard University Hospital. Prior to that Dr. Frederick served as Howard University's Interim President (elected October 2013) after serving as Provost and Chief Academic Officer for more than a year.Following his post doctoral research and surgical oncology fellowships at the University of Texas MD Anderson Cancer Center, Dr. Frederick began his academic career as Associate Director of the Cancer Center at the University of Connecticut. Upon his return to Howard University, his academic positions included Associate Dean in the College of Medicine, Division Chief in the Department of Surgery, Director of the Cancer Center and Deputy Provost for Health Sciences. He also earned a Master of Biness Administration degree from Howard University's School of Biness in 2011.Dr. Frederick is a fellow of the American College of Surgeons (ACS) and belongs to numero surgical and medical organizations, including, the ACS' Academy of Master Surgeon Educators, the American Surgical Association and the National Academy of Medicine. In addition to his public board service, Dr. Frederick also serves on the Board of Directors of Mutual of America Life Insurance Co.
Raquel C. Bono

Raquel C. Bono最初于2020年9月当选为董事会成员。她是RCB咨询公司的负责人,自2019年10月起担任负责人。博诺博士是一名获得董事会认证的创伤外科医生,美国海军医疗队退役副上将,此前曾担任国防卫生局(DHA)首席执行官和局长。在首席执行官和局长职位上,博诺博士领导了一个联合、综合作战支援机构,使美军医疗服务的所有分支机构能够在和平时期和战争时期向作战司令部提供医疗保健服务。博诺博士为陆军、海军、空军和海军陆战队整合了一个前所未有的价值500亿美元的全球医疗企业,由50家医院和300家诊所组成,为950万军人提供医疗服务,监督国防部电子医疗记录的部署,并促进了双方的合作最大的联邦卫生系统的国防部和退伍军人事务部(VA)。博诺博士自1991年起担任美国外科学会(ACS)研究员,曾在ACS理事会和州长健康政策和倡导工作组任职。先后荣获国防杰出服役奖章、国防高级服役奖章3枚、功勋军团奖章4枚、功勋服役奖章2枚、海军陆战队表彰奖章2枚。博诺博士也在几家私人控股公司的董事会任职。


Raquel C. Bono was initially elected to the Board in September 2020. Dr. Bono is a Principal at RCB Consulting having held this position since October 2019, and serves as CEO and Chief of Surgical Innovation at Medical iSight, having held this position since 2023. Dr. Bono was formerly Chief Health Officer at Viking Cruises from November 2020 until her retirement in December 2023.Prior to Viking Cruises, Dr. Bono, a board certified trauma surgeon and retired Vice Admiral, U.S. Navy Medical Corps, served as the Chief Executive Officer and Director for the Defense Health Agency (DHA). In this capacity, Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel, oversaw the Department of Defense deployment of the electronic health record, and facilitated the collaboration beten the largest federated health systems of the Department of Defense and Department of Veterans Affairs (VA).An American College of Surgeons (ACS) Fellow since 1991, Dr. Bono served on the ACS Board of Governors and the Governors Health Policy and Advocacy Workgroup. She has been honored with the Defense Distinguished Service Medal, three Defense Superior Service Medals, f Legion of Merit Medals, two Meritorio Service Medals, and two Navy and Marine Corps Commendation medals.
Raquel C. Bono最初于2020年9月当选为董事会成员。她是RCB咨询公司的负责人,自2019年10月起担任负责人。博诺博士是一名获得董事会认证的创伤外科医生,美国海军医疗队退役副上将,此前曾担任国防卫生局(DHA)首席执行官和局长。在首席执行官和局长职位上,博诺博士领导了一个联合、综合作战支援机构,使美军医疗服务的所有分支机构能够在和平时期和战争时期向作战司令部提供医疗保健服务。博诺博士为陆军、海军、空军和海军陆战队整合了一个前所未有的价值500亿美元的全球医疗企业,由50家医院和300家诊所组成,为950万军人提供医疗服务,监督国防部电子医疗记录的部署,并促进了双方的合作最大的联邦卫生系统的国防部和退伍军人事务部(VA)。博诺博士自1991年起担任美国外科学会(ACS)研究员,曾在ACS理事会和州长健康政策和倡导工作组任职。先后荣获国防杰出服役奖章、国防高级服役奖章3枚、功勋军团奖章4枚、功勋服役奖章2枚、海军陆战队表彰奖章2枚。博诺博士也在几家私人控股公司的董事会任职。
Raquel C. Bono was initially elected to the Board in September 2020. Dr. Bono is a Principal at RCB Consulting having held this position since October 2019, and serves as CEO and Chief of Surgical Innovation at Medical iSight, having held this position since 2023. Dr. Bono was formerly Chief Health Officer at Viking Cruises from November 2020 until her retirement in December 2023.Prior to Viking Cruises, Dr. Bono, a board certified trauma surgeon and retired Vice Admiral, U.S. Navy Medical Corps, served as the Chief Executive Officer and Director for the Defense Health Agency (DHA). In this capacity, Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel, oversaw the Department of Defense deployment of the electronic health record, and facilitated the collaboration beten the largest federated health systems of the Department of Defense and Department of Veterans Affairs (VA).An American College of Surgeons (ACS) Fellow since 1991, Dr. Bono served on the ACS Board of Governors and the Governors Health Policy and Advocacy Workgroup. She has been honored with the Defense Distinguished Service Medal, three Defense Superior Service Medals, f Legion of Merit Medals, two Meritorio Service Medals, and two Navy and Marine Corps Commendation medals.
Marcy S. Klevorn

Marcy S. Klevorn最初于2021年2月当选为董事会成员。Klevorn女士曾于2019年5月担任福特汽车公司的首席转型官,直至2019年10月退休。在首席转型官职位上,她通过帮助完善福特汽车公司治理系统、促进企业更快地采用敏捷团队以及确保整个企业的流程改进,加速了福特汽车公司的转型。她还促进了与关键技术合作伙伴的战略合作,并支持福特汽车公司的多元化努力。Klevorn女士于1983年加入福特汽车公司,担任福特汽车公司信息技术部门的主要执行和领导职务,包括首席信息官办公室主任和集团信息技术副总裁,负责监督福特IT工具和人才的转型。Klevorn女士还曾担任福特汽车公司(Ford Motor Company)旗下的福特智能移动有限责任公司(Ford Smart Mobility LLC)的执行副总裁兼总裁,负责监督某些收购和其他投资,并帮助加快公司在新兴移动服务和全球数据洞察与分析领域的设计、建设、发展和投资计划。Klevorn女士目前在北方信托公司和一些私营公司的董事会任职。


Marcy S. Klevorn was initially elected to the Board in February 2021. Ms. Klevorn was formerly the Chief Transformation Officer of Ford Motor Company from May 2019 until her retirement in October 2019. In this role, she accelerated the company's transformation by helping to refine its corporate governance systems, facilitate faster adoption of agile teams across the biness and ensure process improvements across the enterprise. She also facilitated strategic partnerships with key technology partners and supported the company's diversity efforts. Having joined Ford Motor Company in 1983, Ms. Klevorn served in key executive and leadership roles within the company's information technology organization including Director of the Office of the Chief Information Officer and Group Vice President of Information Technology. Ms. Klevorn also served as Executive Vice President and President of Ford Smart Mobility LLC, a division of Ford Motor Company, where she oversaw certain acquisitions and other investments and helped to accelerate the company's plans to design, build, grow and invest in emerging mobility services and global data insight and analytics.
Marcy S. Klevorn最初于2021年2月当选为董事会成员。Klevorn女士曾于2019年5月担任福特汽车公司的首席转型官,直至2019年10月退休。在首席转型官职位上,她通过帮助完善福特汽车公司治理系统、促进企业更快地采用敏捷团队以及确保整个企业的流程改进,加速了福特汽车公司的转型。她还促进了与关键技术合作伙伴的战略合作,并支持福特汽车公司的多元化努力。Klevorn女士于1983年加入福特汽车公司,担任福特汽车公司信息技术部门的主要执行和领导职务,包括首席信息官办公室主任和集团信息技术副总裁,负责监督福特IT工具和人才的转型。Klevorn女士还曾担任福特汽车公司(Ford Motor Company)旗下的福特智能移动有限责任公司(Ford Smart Mobility LLC)的执行副总裁兼总裁,负责监督某些收购和其他投资,并帮助加快公司在新兴移动服务和全球数据洞察与分析领域的设计、建设、发展和投资计划。Klevorn女士目前在北方信托公司和一些私营公司的董事会任职。
Marcy S. Klevorn was initially elected to the Board in February 2021. Ms. Klevorn was formerly the Chief Transformation Officer of Ford Motor Company from May 2019 until her retirement in October 2019. In this role, she accelerated the company's transformation by helping to refine its corporate governance systems, facilitate faster adoption of agile teams across the biness and ensure process improvements across the enterprise. She also facilitated strategic partnerships with key technology partners and supported the company's diversity efforts. Having joined Ford Motor Company in 1983, Ms. Klevorn served in key executive and leadership roles within the company's information technology organization including Director of the Office of the Chief Information Officer and Group Vice President of Information Technology. Ms. Klevorn also served as Executive Vice President and President of Ford Smart Mobility LLC, a division of Ford Motor Company, where she oversaw certain acquisitions and other investments and helped to accelerate the company's plans to design, build, grow and invest in emerging mobility services and global data insight and analytics.
Gordon Smith

Gordon Smith,担任领先的私人投资公司Clayton,Dubilier & Rice LLC(CD & R)Funds的运营顾问。他此前担任JPMorgan Chase & Co.(JPMorgan)的联席总裁兼联席首席运营官,并担任摩根大通运营委员会成员,从2018年到2022年1月退休,帮助监督公司业务和运营的各个方面。他在摩根大通的职业生涯始于2007年,跨越了15年,在此期间,他还在2012年至2021年期间担任消费者和社区银行业务的首席执行官。在加入摩根大通之前,Smith在美国运通工作了超过25年,在那里他领导并管理了包括全球商业卡业务在内的多项业务。


Gordon Smith was initially elected to the Board in October 2024. Mr. Smith was formerly the Co President and Co Chief Operating Officer of JPMorgan Chase & Co. (JPMorgan), having held these positions from 2018 until retiring in January of 2022. In this role, Mr. Smith served as a member of the firm's Operating Committee and helped oversee all aspects of the company's biness and operations.Mr. Smith's career at JPMorgan began in 2007 and spanned 15 years, where he previoly served as Chief Executive Officer of Consumer & Community Banking (2012 2021), and prior to that held vario roles of increasing responsibility, including as CEO of Chase Card Services, Auto Finance and Student Lending (2011 2012), and CEO of Chase Card Services (2007 2011).Prior to his time at JPMorgan, Mr. Smith spent more than 25 years at American Express, where he led and managed several binesses, including the Global Commercial Card Biness. Mr. Smith is also an operating advisor to Clayton, Dubilier & Rice, LLC.
Gordon Smith,担任领先的私人投资公司Clayton,Dubilier & Rice LLC(CD & R)Funds的运营顾问。他此前担任JPMorgan Chase & Co.(JPMorgan)的联席总裁兼联席首席运营官,并担任摩根大通运营委员会成员,从2018年到2022年1月退休,帮助监督公司业务和运营的各个方面。他在摩根大通的职业生涯始于2007年,跨越了15年,在此期间,他还在2012年至2021年期间担任消费者和社区银行业务的首席执行官。在加入摩根大通之前,Smith在美国运通工作了超过25年,在那里他领导并管理了包括全球商业卡业务在内的多项业务。
Gordon Smith was initially elected to the Board in October 2024. Mr. Smith was formerly the Co President and Co Chief Operating Officer of JPMorgan Chase & Co. (JPMorgan), having held these positions from 2018 until retiring in January of 2022. In this role, Mr. Smith served as a member of the firm's Operating Committee and helped oversee all aspects of the company's biness and operations.Mr. Smith's career at JPMorgan began in 2007 and spanned 15 years, where he previoly served as Chief Executive Officer of Consumer & Community Banking (2012 2021), and prior to that held vario roles of increasing responsibility, including as CEO of Chase Card Services, Auto Finance and Student Lending (2011 2012), and CEO of Chase Card Services (2007 2011).Prior to his time at JPMorgan, Mr. Smith spent more than 25 years at American Express, where he led and managed several binesses, including the Global Commercial Card Biness. Mr. Smith is also an operating advisor to Clayton, Dubilier & Rice, LLC.
Frank A. D Amelio

Frank A. D Amelio,从2010年12月到2022年5月退休,担任辉瑞公司(Pfizer Inc.)的执行副总裁兼首席财务官(“CFO”),这是一家以研究为基础的全球生物制药公司,在此期间,他还负责业务运营和全球供应链。在此之前,他从2007年到2010年12月担任Pfizer的高级副总裁兼首席财务官。在加入Pfizer之前,他曾担任Alcatel-Lucent(一家通信公司)的业务运营和集成高级执行副总裁(2006年12月至2007年8月),以及朗讯科技公司(Lucent Technologies, Inc.)的各种高级领导职务,特别是2001年至2005年担任首席财务官,2005年至2006年担任首席运营官。


Frank A. D Amelio was initially elected to the Board in September 2003. Mr. D'Amelio was formerly Executive Vice President, Chief Financial Officer at Pfizer Inc. having held this position from January 2022 until May 2022. Mr. D'Amelio began his career at Pfizer in 2007 and since then has held vario roles of increasing responsibility, including, SVP & Chief Financial Officer (September 2007 December 2010), Executive Vice President, Biness Operations and Chief Financial Officer (January 2011 October 2018) and Chief Financial Officer and Executive Vice President, Global Supply (November 2018 December 2021).Prior to Pfizer, Mr. D'Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel Lucent from December 2006 to Augt 2007, and Chief Operating Officer of Lucent Technologies Inc. from February 2006 to November 2006. From May 2001 until January 2006, he was Executive Vice President, Administration and Chief Financial Officer of Lucent.
Frank A. D Amelio,从2010年12月到2022年5月退休,担任辉瑞公司(Pfizer Inc.)的执行副总裁兼首席财务官(“CFO”),这是一家以研究为基础的全球生物制药公司,在此期间,他还负责业务运营和全球供应链。在此之前,他从2007年到2010年12月担任Pfizer的高级副总裁兼首席财务官。在加入Pfizer之前,他曾担任Alcatel-Lucent(一家通信公司)的业务运营和集成高级执行副总裁(2006年12月至2007年8月),以及朗讯科技公司(Lucent Technologies, Inc.)的各种高级领导职务,特别是2001年至2005年担任首席财务官,2005年至2006年担任首席运营官。
Frank A. D Amelio was initially elected to the Board in September 2003. Mr. D'Amelio was formerly Executive Vice President, Chief Financial Officer at Pfizer Inc. having held this position from January 2022 until May 2022. Mr. D'Amelio began his career at Pfizer in 2007 and since then has held vario roles of increasing responsibility, including, SVP & Chief Financial Officer (September 2007 December 2010), Executive Vice President, Biness Operations and Chief Financial Officer (January 2011 October 2018) and Chief Financial Officer and Executive Vice President, Global Supply (November 2018 December 2021).Prior to Pfizer, Mr. D'Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel Lucent from December 2006 to Augt 2007, and Chief Operating Officer of Lucent Technologies Inc. from February 2006 to November 2006. From May 2001 until January 2006, he was Executive Vice President, Administration and Chief Financial Officer of Lucent.
Kurt J. Hilzinger

Kurt J. Hilzinger, 2003年7月被选为董事会成员,2014年1月1日被选为董事会主席。他从2010年8月起担任首席董事,直到被任命为董事长。他是Court Square Capital Partners(一家独立的私募股权公司)的合伙人,自2007年11月起担任该职位。在Court Square,他主要专注于医疗保健行业的投资。在此之前,他从2004年3月到2007年11月担任AmerisourceBergen Corporation的董事;2002年10月至2007年11月担任AmerisourceBergen Corporation的总裁兼首席运营官,2001年8月至2002年10月担任执行副总裁兼首席运营官。他还担任Outlook Therapeutics, Inc.和几家私人控股公司的董事会成员。


Kurt J. Hilzinger was initially elected to the Board in July 2003 and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from Augt 2010 until his appointment as Chairman. Mr. Hilzinger is an Executive Advisor and former Partner at Ct Square Capital Partners (Ct Square), an independent private equity firm, having held this position since November 2007. At Ct Square, Mr. Hilzinger foces principally on investments in the healthcare indtry.Prior to Ct Square, Mr. Hilzinger was a Director of AmerisceBergen Corporation from March 2004 to November 2007; having previoly served as President and Chief Operating Officer of AmerisceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from Augt 2001 to October 2002. As a distinguished financial executive and operator, Mr. Hilzinger led the recapitalization and initial public offering or Amerisce Health Corp. and the successful integration or Amerisce Health Corp. and Bergen Brunswig Corp. in the creation of AmerisceBergen Corp. (now Cencora Corp.). In addition to his integration responsibilities, Mr. Hilzinger held enterprise wide P&L responsibility while overseeing the integration of 30+ acquisitions and the transformation of the biness model to fee or services. Mr. Hilzinger has significant government affairs experience interacting with the FTC, the FDA, and the DEA, and while serving as Chairman of the Healthcare Distribution Alliance (HDA). Mr. Hilzinger is a thought leader in the healthcare sector, with a successful career track record of investments in pharmaceutical services and commercialization.
Kurt J. Hilzinger, 2003年7月被选为董事会成员,2014年1月1日被选为董事会主席。他从2010年8月起担任首席董事,直到被任命为董事长。他是Court Square Capital Partners(一家独立的私募股权公司)的合伙人,自2007年11月起担任该职位。在Court Square,他主要专注于医疗保健行业的投资。在此之前,他从2004年3月到2007年11月担任AmerisourceBergen Corporation的董事;2002年10月至2007年11月担任AmerisourceBergen Corporation的总裁兼首席运营官,2001年8月至2002年10月担任执行副总裁兼首席运营官。他还担任Outlook Therapeutics, Inc.和几家私人控股公司的董事会成员。
Kurt J. Hilzinger was initially elected to the Board in July 2003 and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from Augt 2010 until his appointment as Chairman. Mr. Hilzinger is an Executive Advisor and former Partner at Ct Square Capital Partners (Ct Square), an independent private equity firm, having held this position since November 2007. At Ct Square, Mr. Hilzinger foces principally on investments in the healthcare indtry.Prior to Ct Square, Mr. Hilzinger was a Director of AmerisceBergen Corporation from March 2004 to November 2007; having previoly served as President and Chief Operating Officer of AmerisceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from Augt 2001 to October 2002. As a distinguished financial executive and operator, Mr. Hilzinger led the recapitalization and initial public offering or Amerisce Health Corp. and the successful integration or Amerisce Health Corp. and Bergen Brunswig Corp. in the creation of AmerisceBergen Corp. (now Cencora Corp.). In addition to his integration responsibilities, Mr. Hilzinger held enterprise wide P&L responsibility while overseeing the integration of 30+ acquisitions and the transformation of the biness model to fee or services. Mr. Hilzinger has significant government affairs experience interacting with the FTC, the FDA, and the DEA, and while serving as Chairman of the Healthcare Distribution Alliance (HDA). Mr. Hilzinger is a thought leader in the healthcare sector, with a successful career track record of investments in pharmaceutical services and commercialization.
David T. Feinberg

David T. Feinberg,最初于2022年3月当选为董事会成员。Feinberg博士是甲骨文健康公司的董事长,他致力于使医疗保健更容易获得、负担得起和公平。他的工作推进了思想领导力和战略,通过开放和连接的医疗保健生态系统释放数据的治愈力量。此前,他曾担任Cerner Corporation(现为Oracle Health)的总裁、首席执行官和董事会成员。在这个职位上,Feinberg博士专注于提供工具和技术,帮助护理人员优化患者和社区的健康。Feinberg从谷歌加入Cerner,自2019年以来,他担任谷歌Health副总裁,领导谷歌的全球健康工作,将谷歌和Alphabet的团队聚集在一起,Humana Inc.利用人工智能、产品专业知识和硬件来应对医疗保健领域的一些最大挑战,并负责组织和创新谷歌的各种医疗保健计划。在b谷歌之前,他曾担任Geisinger Health的总裁兼首席执行官,在那里他领导了运营转型,并推动了Humana Inc. e的新平台和工具,包括称为统一数据架构的IT系统,该系统允许公司将大数据集成到现有的数据分析和管理系统中。在Geisinger任职期间,Feinberg博士还引入了一些项目和服务,以更加关注精准医疗和更好的患者护理。在加入Geisinger之前,Feinberg博士在加州大学洛杉矶分校工作了20多年,担任过许多领导职务,包括加州大学洛杉矶分校健康科学的总裁、首席执行官和副校长,加州大学洛杉矶分校医院系统的副校长和首席执行官,加州大学洛杉矶分校罗纳德·里根医疗中心的首席执行官。Feinberg在加州大学伯克利分校获得本科学位。他以优异的成绩毕业于健康科学大学/芝加哥医学院。他在洛约拉大学医学中心完成了儿科实习,并在加州大学洛杉矶分校医学院完成了精神病学、成瘾精神病学、儿童和青少年精神病学的住院医师和奖学金培训。他获得了佩珀代因大学的工商管理硕士学位。Feinberg博士是Alpha Omega Alpha医学荣誉协会的成员,美国精神病学协会的杰出会员,并获得美国儿童与青少年精神病学学会颁发的Cancro学术领导奖。他还担任Douglas Emmett Inc.的董事会成员。


David T. Feinberg was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing por of data through an open and connected healthcare ecosystem. Previoly, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg foced on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's vario healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and phed the e of new platforms and tools, including an IT system called a Unified Data Architecture that allod the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater foc on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Biness Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry.
David T. Feinberg,最初于2022年3月当选为董事会成员。Feinberg博士是甲骨文健康公司的董事长,他致力于使医疗保健更容易获得、负担得起和公平。他的工作推进了思想领导力和战略,通过开放和连接的医疗保健生态系统释放数据的治愈力量。此前,他曾担任Cerner Corporation(现为Oracle Health)的总裁、首席执行官和董事会成员。在这个职位上,Feinberg博士专注于提供工具和技术,帮助护理人员优化患者和社区的健康。Feinberg从谷歌加入Cerner,自2019年以来,他担任谷歌Health副总裁,领导谷歌的全球健康工作,将谷歌和Alphabet的团队聚集在一起,Humana Inc.利用人工智能、产品专业知识和硬件来应对医疗保健领域的一些最大挑战,并负责组织和创新谷歌的各种医疗保健计划。在b谷歌之前,他曾担任Geisinger Health的总裁兼首席执行官,在那里他领导了运营转型,并推动了Humana Inc. e的新平台和工具,包括称为统一数据架构的IT系统,该系统允许公司将大数据集成到现有的数据分析和管理系统中。在Geisinger任职期间,Feinberg博士还引入了一些项目和服务,以更加关注精准医疗和更好的患者护理。在加入Geisinger之前,Feinberg博士在加州大学洛杉矶分校工作了20多年,担任过许多领导职务,包括加州大学洛杉矶分校健康科学的总裁、首席执行官和副校长,加州大学洛杉矶分校医院系统的副校长和首席执行官,加州大学洛杉矶分校罗纳德·里根医疗中心的首席执行官。Feinberg在加州大学伯克利分校获得本科学位。他以优异的成绩毕业于健康科学大学/芝加哥医学院。他在洛约拉大学医学中心完成了儿科实习,并在加州大学洛杉矶分校医学院完成了精神病学、成瘾精神病学、儿童和青少年精神病学的住院医师和奖学金培训。他获得了佩珀代因大学的工商管理硕士学位。Feinberg博士是Alpha Omega Alpha医学荣誉协会的成员,美国精神病学协会的杰出会员,并获得美国儿童与青少年精神病学学会颁发的Cancro学术领导奖。他还担任Douglas Emmett Inc.的董事会成员。
David T. Feinberg was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing por of data through an open and connected healthcare ecosystem. Previoly, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg foced on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's vario healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and phed the e of new platforms and tools, including an IT system called a Unified Data Architecture that allod the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater foc on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Biness Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry.
Jorge S. Mesquita

Jorge S. Mesquita,最初于2021年2月当选为董事会成员。他曾担任BlueTriton Brands的首席执行官(从2021年7月到2022年3月)。在此职位上,Mesquita先生领导公司扩大市场领导地位,推进对可持续发展和环境管理的承诺,并实现公司水品牌组合的潜力。在加入BlueTriton Brands之前,Mesquita先生曾于2014年12月至2019年2月担任强生公司(J&J)的执行副总裁兼全球消费者主席,负责通过全面的转型战略提高强生消费者业务的竞争力。在此职位上,他曾任职于J&J的执行委员会,并领导消费者集团运营委员会。在此之前,他在宝洁公司(P&G)工作了29年,在那里他担任领导宝洁消费品业务部门的各种职务。在宝洁任职期间,他曾担任新业务创造和创新集团总裁(2012年3月至2013年6月),集团总裁(2012年1月至2012年3月),特别任务集团总裁(2012年1月至2012年3月),全球织物护理集团总裁(2007年至2011年),全球家庭护理总裁(2001年至2007年),还担任商业产品总裁和宝洁专业总裁(2006年至2007年)。他目前担任Mondelez International, Inc.的董事会成员。


Jorge S. Mesquita was initially elected to the Board in February 2021. Mr. Mesquita was formerly Chief Executive Officer of BlueTriton Brands, from July 2021 until March 2022. In this role Mr. Mesquita led the company's initiatives to expand market leadership, advance commitment to stainability and environmental stewardship and to realize the potential of the company's portfolio of water brands.Prior to joining BlueTriton Brands, Mr. Mesquita was formerly the Executive Vice President, Worldwide Chairman, Consumer of Johnson & Johnson (J&J), from December 2014 until February 2019, where he was responsible for increasing competition within J&J's consumer biness through a comprehensive transformational strategy. In this role, Mr. Mesquita served on J&J's Executive Committee and led the Consumer Group Operating Committee. Prior to that, Mr. Mesquita was employed by The Procter & Gamble Company (P&G), where he held vario marketing and leadership positions for 29 years from 1984 to 2013. During his tenure at P&G, Mr. Mesquita served as Group President—New Biness Creation and Innovation from March 2012 until June 2013, Group President—Special Assignment from January 2012 until March 2012, Group President, Global Fabric Care from 2007 to 2011 and President, Global Home Care from 2001 to 2007, also serving as President of Commercial Products and President of P&G Professional from 2006 to 2007.
Jorge S. Mesquita,最初于2021年2月当选为董事会成员。他曾担任BlueTriton Brands的首席执行官(从2021年7月到2022年3月)。在此职位上,Mesquita先生领导公司扩大市场领导地位,推进对可持续发展和环境管理的承诺,并实现公司水品牌组合的潜力。在加入BlueTriton Brands之前,Mesquita先生曾于2014年12月至2019年2月担任强生公司(J&J)的执行副总裁兼全球消费者主席,负责通过全面的转型战略提高强生消费者业务的竞争力。在此职位上,他曾任职于J&J的执行委员会,并领导消费者集团运营委员会。在此之前,他在宝洁公司(P&G)工作了29年,在那里他担任领导宝洁消费品业务部门的各种职务。在宝洁任职期间,他曾担任新业务创造和创新集团总裁(2012年3月至2013年6月),集团总裁(2012年1月至2012年3月),特别任务集团总裁(2012年1月至2012年3月),全球织物护理集团总裁(2007年至2011年),全球家庭护理总裁(2001年至2007年),还担任商业产品总裁和宝洁专业总裁(2006年至2007年)。他目前担任Mondelez International, Inc.的董事会成员。
Jorge S. Mesquita was initially elected to the Board in February 2021. Mr. Mesquita was formerly Chief Executive Officer of BlueTriton Brands, from July 2021 until March 2022. In this role Mr. Mesquita led the company's initiatives to expand market leadership, advance commitment to stainability and environmental stewardship and to realize the potential of the company's portfolio of water brands.Prior to joining BlueTriton Brands, Mr. Mesquita was formerly the Executive Vice President, Worldwide Chairman, Consumer of Johnson & Johnson (J&J), from December 2014 until February 2019, where he was responsible for increasing competition within J&J's consumer biness through a comprehensive transformational strategy. In this role, Mr. Mesquita served on J&J's Executive Committee and led the Consumer Group Operating Committee. Prior to that, Mr. Mesquita was employed by The Procter & Gamble Company (P&G), where he held vario marketing and leadership positions for 29 years from 1984 to 2013. During his tenure at P&G, Mr. Mesquita served as Group President—New Biness Creation and Innovation from March 2012 until June 2013, Group President—Special Assignment from January 2012 until March 2012, Group President, Global Fabric Care from 2007 to 2011 and President, Global Home Care from 2001 to 2007, also serving as President of Commercial Products and President of P&G Professional from 2006 to 2007.

高管简历

中英对照 |  中文 |  英文
James A. Rechtin

James A. Rechtin, 2011年加入Humana, 2013年担任首席执行官。在过去的十年中,他领导公司从一家健康保险公司转型为今天的更广泛的医疗保健公司,将健康保险与医疗保健服务相结合。Rechtin从Envision Healthcare加入Humana,担任总裁兼首席执行官。他拥有超过22年的医疗保健经验,专注于在各种医疗集团环境中提供基于价值的护理,包括对医疗保险优势的深刻理解。加入Envision之前,Rechtin担任OptumCare (UnitedHealth Group的一部分)的总裁。在加入OptumCare之前,Rechtin于2014年加入DaVita Medical Group,担任战略高级副总裁和DaVita Medical Group加利福尼亚市场总裁。此外,他是Bain & Company的14年资深员工,突出了他在医疗保健合并和整体医疗保健行业的丰富经验。雷克廷是肯塔基人,他的职业生涯始于印第安纳波利斯一家非营利性健康和人类服务诊所的运营,并在刚果的美国和平队服役。他获得了哈佛商学院工商管理硕士学位和德堡大学文学学士学位。他担任DePauw board of Visitors的董事会成员。


James A. Rechtin joined Humana in January 2024, having served as President and Chief Operating Officer until July 2024. Under his leadership, Humana operates as a leading integrated care delivery model centered on improving health outcomes, driving lor costs, enhancing quality, and providing a simple and personalized member and patient experience.Prior to joining Humana, Mr. Rechtin served as President and CEO at Envision Healthcare. He has more than 22 years of health care experience with a foc on the delivery of value based care in vario medical group settings, including a deep understanding of Medicare Advantage. Prior to joining Envision, Mr. Rechtin served as President of OptumCare, part of UnitedHealth Group. Before that, Mr. Rechtin was with DaVita Medical Group and played the dual roles of Senior Vice President of Corporate Strategy and President of DaVita Medical Group's California market.
James A. Rechtin, 2011年加入Humana, 2013年担任首席执行官。在过去的十年中,他领导公司从一家健康保险公司转型为今天的更广泛的医疗保健公司,将健康保险与医疗保健服务相结合。Rechtin从Envision Healthcare加入Humana,担任总裁兼首席执行官。他拥有超过22年的医疗保健经验,专注于在各种医疗集团环境中提供基于价值的护理,包括对医疗保险优势的深刻理解。加入Envision之前,Rechtin担任OptumCare (UnitedHealth Group的一部分)的总裁。在加入OptumCare之前,Rechtin于2014年加入DaVita Medical Group,担任战略高级副总裁和DaVita Medical Group加利福尼亚市场总裁。此外,他是Bain & Company的14年资深员工,突出了他在医疗保健合并和整体医疗保健行业的丰富经验。雷克廷是肯塔基人,他的职业生涯始于印第安纳波利斯一家非营利性健康和人类服务诊所的运营,并在刚果的美国和平队服役。他获得了哈佛商学院工商管理硕士学位和德堡大学文学学士学位。他担任DePauw board of Visitors的董事会成员。
James A. Rechtin joined Humana in January 2024, having served as President and Chief Operating Officer until July 2024. Under his leadership, Humana operates as a leading integrated care delivery model centered on improving health outcomes, driving lor costs, enhancing quality, and providing a simple and personalized member and patient experience.Prior to joining Humana, Mr. Rechtin served as President and CEO at Envision Healthcare. He has more than 22 years of health care experience with a foc on the delivery of value based care in vario medical group settings, including a deep understanding of Medicare Advantage. Prior to joining Envision, Mr. Rechtin served as President of OptumCare, part of UnitedHealth Group. Before that, Mr. Rechtin was with DaVita Medical Group and played the dual roles of Senior Vice President of Corporate Strategy and President of DaVita Medical Group's California market.
Celeste M. Mellet

Celeste M. Mellet,目前担任Global Infrastructure Partners(GIP)的首席财务官,这是一家领先的基础设施基金管理公司,最近被BlackRock收购。在加入GIP之前,她是Evercore的首席财务官、高级董事总经理兼执行副总裁,负责Evercore的财务、战略、税务、信息技术和设施职能。在加入Evercore之前,Mellet是Fannie Mae的执行副总裁兼首席财务官,负责Fannie Mae战略和财务管理职能。在任职Fannie Mae之前,她在Morgan Stanley工作了超过18年,最后担任全球财务主管,此前担任投资者、债权人和交易对手关系主管。Mellet此前也是一名股票研究分析师,覆盖金融、媒体和博彩住宿领域。


Celeste M. Mellet currently serves as Chief Financial Officer, having been elected to this position in January 2025. Prior to joining the Company, Ms. Mellet served as Partner and Chief Financial Officer of Global Infrastructure Partners (GIP) from February 2023 to January 2025. Prior to GIP, Ms. Mellet served as Chief Financial Officer, Senior Managing Director and an Executive Vice President at Evercore from 2021 to 2023. Before joining Evercore, Ms. Mellet served as Executive Vice President and Chief Financial Officer from 2018 to 2021 and SVP and Deputy Chief Financial Officer from 2017 to 2018 at the Federal National Mortgage Association (Fannie Mae). Before her tenure at Fannie Mae, Ms. Mellet spent more than 18 years at Morgan Stanley, last serving as global treasurer. She was also the head of investor, creditor and counterparty relations.
Celeste M. Mellet,目前担任Global Infrastructure Partners(GIP)的首席财务官,这是一家领先的基础设施基金管理公司,最近被BlackRock收购。在加入GIP之前,她是Evercore的首席财务官、高级董事总经理兼执行副总裁,负责Evercore的财务、战略、税务、信息技术和设施职能。在加入Evercore之前,Mellet是Fannie Mae的执行副总裁兼首席财务官,负责Fannie Mae战略和财务管理职能。在任职Fannie Mae之前,她在Morgan Stanley工作了超过18年,最后担任全球财务主管,此前担任投资者、债权人和交易对手关系主管。Mellet此前也是一名股票研究分析师,覆盖金融、媒体和博彩住宿领域。
Celeste M. Mellet currently serves as Chief Financial Officer, having been elected to this position in January 2025. Prior to joining the Company, Ms. Mellet served as Partner and Chief Financial Officer of Global Infrastructure Partners (GIP) from February 2023 to January 2025. Prior to GIP, Ms. Mellet served as Chief Financial Officer, Senior Managing Director and an Executive Vice President at Evercore from 2021 to 2023. Before joining Evercore, Ms. Mellet served as Executive Vice President and Chief Financial Officer from 2018 to 2021 and SVP and Deputy Chief Financial Officer from 2017 to 2018 at the Federal National Mortgage Association (Fannie Mae). Before her tenure at Fannie Mae, Ms. Mellet spent more than 18 years at Morgan Stanley, last serving as global treasurer. She was also the head of investor, creditor and counterparty relations.
Joseph C. Ventura

Joseph C. Ventura目前担任首席法律官和公司秘书。 彼于二零零九年一月加入本公司,并于二零零九年七月至二零一九年二月期间担任本公司法律部门的多个职位,包括最近担任高级副总裁,副总法律顾问及公司秘书。


Joseph C. Ventura currently serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held vario positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel & Corporate Secretary from July 2017 until February 2019.
Joseph C. Ventura目前担任首席法律官和公司秘书。 彼于二零零九年一月加入本公司,并于二零零九年七月至二零一九年二月期间担任本公司法律部门的多个职位,包括最近担任高级副总裁,副总法律顾问及公司秘书。
Joseph C. Ventura currently serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held vario positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel & Corporate Secretary from July 2017 until February 2019.
Michelle A. O'Hara

Michelle A. O'Hara目前担任首席人力资源官,该职位于2025年1月当选。在加入公司之前,O'Hara女士于2019年至2025年在科学应用国际公司(SAIC)担任执行副总裁兼首席人力资源官。在2019年成为首席人力资源官之前,O'Hara女士在上汽集团担任过各种职责不断增加的角色,包括人才获取、综合人才管理、总奖励和人力资源。


Michelle A. O'Hara,is the Chief Human Resources Officer of Humana Inc., a position she has held since January 1, 2025. In this role, Michelle is responsible for leading Humana's enterprise talent and culture strategy and people programs. Before that, she served as Executive Vice President and Chief Human Resources Officer for Science Applications International Corporation, Inc. ("SAIC"), a technology integrator and leader in digital transformation for federal government customers, a position she held from 2019 until 2024. Ms. O'Hara led SAIC's human capital capabilities, including organizational design, culture transformation, talent management, upskilling and diversity, equity, and inclusion, as well as its marketing, communications and ESG functions. Before that, she held various executive-level positions at SAIC including Senior Vice President, Human Resources from 2018 until 2019 and Senior Vice President, Total Rewards from 2016 until 2018. Before SAIC, she served in senior leadership roles at global professional services and technology companies including BearingPoint, Perot Systems Corporation and Booz Allen Hamilton. Ms. O'Hara currently serves on the board of directors for the CHRO Association, the leading organization of large company Chief Human Resources Officers. Ms. O'Hara received her B.S. from the College of William and Mary.
Michelle A. O'Hara目前担任首席人力资源官,该职位于2025年1月当选。在加入公司之前,O'Hara女士于2019年至2025年在科学应用国际公司(SAIC)担任执行副总裁兼首席人力资源官。在2019年成为首席人力资源官之前,O'Hara女士在上汽集团担任过各种职责不断增加的角色,包括人才获取、综合人才管理、总奖励和人力资源。
Michelle A. O'Hara,is the Chief Human Resources Officer of Humana Inc., a position she has held since January 1, 2025. In this role, Michelle is responsible for leading Humana's enterprise talent and culture strategy and people programs. Before that, she served as Executive Vice President and Chief Human Resources Officer for Science Applications International Corporation, Inc. ("SAIC"), a technology integrator and leader in digital transformation for federal government customers, a position she held from 2019 until 2024. Ms. O'Hara led SAIC's human capital capabilities, including organizational design, culture transformation, talent management, upskilling and diversity, equity, and inclusion, as well as its marketing, communications and ESG functions. Before that, she held various executive-level positions at SAIC including Senior Vice President, Human Resources from 2018 until 2019 and Senior Vice President, Total Rewards from 2016 until 2018. Before SAIC, she served in senior leadership roles at global professional services and technology companies including BearingPoint, Perot Systems Corporation and Booz Allen Hamilton. Ms. O'Hara currently serves on the board of directors for the CHRO Association, the leading organization of large company Chief Human Resources Officers. Ms. O'Hara received her B.S. from the College of William and Mary.
George Renaudin II

George Renaudin II目前担任医疗保险和医疗补助总裁,于2023年2月当选担任这一职务。他于2004年4月加入公司,此后担任各种领导职务,责任日益增加,最近担任医疗保险总裁。


George Renaudin II currently serves as President, Insurance, having been elected to this position in October 2024 from his prior role as President, Medicare & Medicaid. Mr. Renaudin joined the Company in April 2004 and since then has held vario leadership roles of increasing responsibility, including previoly holding the position of President, Medicare.
George Renaudin II目前担任医疗保险和医疗补助总裁,于2023年2月当选担任这一职务。他于2004年4月加入公司,此后担任各种领导职务,责任日益增加,最近担任医疗保险总裁。
George Renaudin II currently serves as President, Insurance, having been elected to this position in October 2024 from his prior role as President, Medicare & Medicaid. Mr. Renaudin joined the Company in April 2004 and since then has held vario leadership roles of increasing responsibility, including previoly holding the position of President, Medicare.
John Paul W. Felter

John Paul W. Felter目前担任高级副总裁、首席会计官和财务总监,已于2022年8月当选。加入Humana Inc.公司之前,Felter先生于2022年5月至2022年6月担任OneAmerica Financial Partners,Inc.的投资融资高级总监。在加入OneAmerica之前,Felter先生在安永会计师事务所(Ernst&Young LLP)担任了近11年的高级经理,负责监督公共和私人实体的大型审计业务,专注于医疗保险行业。


John Paul W. Felter currently serves as Senior Vice President, Chief Accounting Officer and Controller, having been elected to this position in Augt 2022. Before joining the Company, Mr. Felter served as Senior Director Investment Finance for OneAmerica Financial Partners, Inc. in 2022. Prior to OneAmerica, Mr. Felter spent nearly 11 years in multiple roles of increasing responsibility at Ernst & Young LLP where he oversaw large audit engagements for public and private entities with a concentration in the health insurance sector.
John Paul W. Felter目前担任高级副总裁、首席会计官和财务总监,已于2022年8月当选。加入Humana Inc.公司之前,Felter先生于2022年5月至2022年6月担任OneAmerica Financial Partners,Inc.的投资融资高级总监。在加入OneAmerica之前,Felter先生在安永会计师事务所(Ernst&Young LLP)担任了近11年的高级经理,负责监督公共和私人实体的大型审计业务,专注于医疗保险行业。
John Paul W. Felter currently serves as Senior Vice President, Chief Accounting Officer and Controller, having been elected to this position in Augt 2022. Before joining the Company, Mr. Felter served as Senior Director Investment Finance for OneAmerica Financial Partners, Inc. in 2022. Prior to OneAmerica, Mr. Felter spent nearly 11 years in multiple roles of increasing responsibility at Ernst & Young LLP where he oversaw large audit engagements for public and private entities with a concentration in the health insurance sector.
Sanjay K. Shetty

Sanjay K. Shetty,目前担任CenterWell总裁,已于2023年4月当选这一职位。在加入公司之前,Shetty博士在Steward Health Care System工作了近13年,担任过多个高级职务,包括Steward North America总裁、Steward South Region总裁和执行副总裁、Steward Medical Group总裁和Steward Health Care System执行副总裁、企业和业务发展执行副总裁以及Steward Health Care Network总裁。


Sanjay K. Shetty currently serves as President, Centerll, having been elected to this position in April 2023. Prior to joining the Company, Dr. Shetty worked in health care delivery for nearly 13 years at Steward Health Care System (Steward), most recently serving as President. During his tenure at Steward, Dr. Shetty held vario roles of increasing responsibility, leading the large accountable care organization, a multispecialty group practice, and acute care hospitals. Prior to Steward, Dr. Shetty worked as a strategy consultant at Bain & Company, Inc., and practiced as a radiologist and a faculty member at Harvard Medical School.
Sanjay K. Shetty,目前担任CenterWell总裁,已于2023年4月当选这一职位。在加入公司之前,Shetty博士在Steward Health Care System工作了近13年,担任过多个高级职务,包括Steward North America总裁、Steward South Region总裁和执行副总裁、Steward Medical Group总裁和Steward Health Care System执行副总裁、企业和业务发展执行副总裁以及Steward Health Care Network总裁。
Sanjay K. Shetty currently serves as President, Centerll, having been elected to this position in April 2023. Prior to joining the Company, Dr. Shetty worked in health care delivery for nearly 13 years at Steward Health Care System (Steward), most recently serving as President. During his tenure at Steward, Dr. Shetty held vario roles of increasing responsibility, leading the large accountable care organization, a multispecialty group practice, and acute care hospitals. Prior to Steward, Dr. Shetty worked as a strategy consultant at Bain & Company, Inc., and practiced as a radiologist and a faculty member at Harvard Medical School.
David E. Dintenfass

David E. Dintenfass目前担任Enterprise Growth总裁,于2024年2月加入公司。在加入公司之前,Dintenfass先生曾于2015年至2024年在Fidelity Investments担任一系列领导职务,最近担任执行副总裁、产品和新兴部门主管,领导零售和工作场所投资的损益投资组合。Dintenfass先生还曾担任Fidelity的首席营销官和CTomer Experience Design的负责人。在加入富达之前,丁滕法斯在美国银行工作了五年多,在消费者和小型BINY银行以及美林健康管理公司担任过各种战略和营销职务。在其职业生涯的早期,Dintenfass先生在宝洁工作了13年,担任全球损益和品牌管理职务,责任越来越大。丁滕法斯先生的职业生涯始于麦肯锡公司的顾问。


David E. Dintenfass currently serves as President, Enterprise Growth, having joined the Company in February 2024. Prior to joining the Company, Mr. Dintenfass had a series of leadership roles at Fidelity Investments from 2015 to 2024 where he most recently served as Executive Vice President, Head of Product and Emerging Segments, leading a P&L portfolio across retail and workplace investing. Mr. Dintenfass also served as Fidelity's Chief Marketing Officer and Head of Ctomer Experience Design. Before Fidelity, Mr. Dintenfass spent over five years at Bank of America in a variety of strategy and marketing roles across Consumer and Small Biness banking and Merrill Lynch alth Management. Earlier in his career, Mr. Dintenfass spent 13 years at Procter & Gamble in global P&L and brand management roles of increasing responsibility. Mr. Dintenfass began his career as a consultant at McKinsey & Company.
David E. Dintenfass目前担任Enterprise Growth总裁,于2024年2月加入公司。在加入公司之前,Dintenfass先生曾于2015年至2024年在Fidelity Investments担任一系列领导职务,最近担任执行副总裁、产品和新兴部门主管,领导零售和工作场所投资的损益投资组合。Dintenfass先生还曾担任Fidelity的首席营销官和CTomer Experience Design的负责人。在加入富达之前,丁滕法斯在美国银行工作了五年多,在消费者和小型BINY银行以及美林健康管理公司担任过各种战略和营销职务。在其职业生涯的早期,Dintenfass先生在宝洁工作了13年,担任全球损益和品牌管理职务,责任越来越大。丁滕法斯先生的职业生涯始于麦肯锡公司的顾问。
David E. Dintenfass currently serves as President, Enterprise Growth, having joined the Company in February 2024. Prior to joining the Company, Mr. Dintenfass had a series of leadership roles at Fidelity Investments from 2015 to 2024 where he most recently served as Executive Vice President, Head of Product and Emerging Segments, leading a P&L portfolio across retail and workplace investing. Mr. Dintenfass also served as Fidelity's Chief Marketing Officer and Head of Ctomer Experience Design. Before Fidelity, Mr. Dintenfass spent over five years at Bank of America in a variety of strategy and marketing roles across Consumer and Small Biness banking and Merrill Lynch alth Management. Earlier in his career, Mr. Dintenfass spent 13 years at Procter & Gamble in global P&L and brand management roles of increasing responsibility. Mr. Dintenfass began his career as a consultant at McKinsey & Company.
Japan A. Mehta

Japan A. Mehta,目前担任首席信息官,已于2025年2月当选该职位。在加入公司之前,Mehta先生于2018年至2025年期间在花旗集团担任了六年的首席数据官。此前,他曾在花旗全球财富的多个客户群中担任首席信息官一职。此外,他还曾担任Global Consumer技术亚太和欧洲的首席信息官。在加入花旗之前,Mehta先生曾在摩根大通、巴克莱银行和威瑞森通信担任技术和数字领导职务。


Japan A. Mehta currently serves as Chief Information Officer, having been elected to this position in February 2025. Prior to joining the Company, Mr. Mehta served as Chief Data Officer at Citigroup for six years from 2018 to 2025. Previoly, he held the role of CIO for Citi Global alth across a mix of client segments. Additionally, he served in the CIO role for Global Consumer Technology in Asia Pacific and Europe. Prior to Citi, Mr. Mehta held technology and digital leadership roles at JPMorgan, Barclays and Verizon.
Japan A. Mehta,目前担任首席信息官,已于2025年2月当选该职位。在加入公司之前,Mehta先生于2018年至2025年期间在花旗集团担任了六年的首席数据官。此前,他曾在花旗全球财富的多个客户群中担任首席信息官一职。此外,他还曾担任Global Consumer技术亚太和欧洲的首席信息官。在加入花旗之前,Mehta先生曾在摩根大通、巴克莱银行和威瑞森通信担任技术和数字领导职务。
Japan A. Mehta currently serves as Chief Information Officer, having been elected to this position in February 2025. Prior to joining the Company, Mr. Mehta served as Chief Data Officer at Citigroup for six years from 2018 to 2025. Previoly, he held the role of CIO for Citi Global alth across a mix of client segments. Additionally, he served in the CIO role for Global Consumer Technology in Asia Pacific and Europe. Prior to Citi, Mr. Mehta held technology and digital leadership roles at JPMorgan, Barclays and Verizon.
Aaron C. Martin

Aaron C. Martin目前担任Medicare Advantage总裁,于2026年1月当选该职位。在加入公司之前,Martin先生曾在2022年至2025年期间担任亚马逊,Inc.的医疗保健副总裁。Previoly,Martin先生受雇于Providence St. Joseph Health,该公司在2014年至2022年期间担任越来越多的职责,最近担任Providence Ventures的执行副总裁、首席数字官和管理普通合伙人。


Aaron C. Martin currently serves as President, Medicare Advantage, having been elected to this position in January 2026. Prior to joining the Company, Mr. Martin served as Vice President, Healthcare for Amazon.com, Inc. for f years from 2022 through 2025. Previoly, Mr. Martin was employed at Providence St. Joseph Health, where held roles of increasing responsibility from 2014 through 2022, and most recently served as EVP, Chief Digital Officer and Managing General Partner for Providence Ventures.
Aaron C. Martin目前担任Medicare Advantage总裁,于2026年1月当选该职位。在加入公司之前,Martin先生曾在2022年至2025年期间担任亚马逊,Inc.的医疗保健副总裁。Previoly,Martin先生受雇于Providence St. Joseph Health,该公司在2014年至2022年期间担任越来越多的职责,最近担任Providence Ventures的执行副总裁、首席数字官和管理普通合伙人。
Aaron C. Martin currently serves as President, Medicare Advantage, having been elected to this position in January 2026. Prior to joining the Company, Mr. Martin served as Vice President, Healthcare for Amazon.com, Inc. for f years from 2022 through 2025. Previoly, Mr. Martin was employed at Providence St. Joseph Health, where held roles of increasing responsibility from 2014 through 2022, and most recently served as EVP, Chief Digital Officer and Managing General Partner for Providence Ventures.